Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L
Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V H or V K domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
1. A method of treating an immune disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of an antibody polypeptide comprising a first variable domain comprising the amino acid sequence of BMS2h-572-633 (SEQ ID NO: 274), wherein the immune disease is selected from the group consisting of: immune thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE), proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), Crohn's disease, atheroselerosis, graft-vs-host disease (GVHD), and myasthenia gravis.
2. The method of claim 1 , wherein the antibody polypeptide is administered in combination with an immunosuppressive/immunomodulatory and/or anti-inflammatory agent.
3. The method of claim 1 , wherein the immune disease is systemic lupus erythematosus.
4. The method of claim 1 , wherein the immune disease is idiopathic thrombocytopenic purpura.
5. The method of claim 1 , wherein the immune disease is proliferative lupus glomerulonephritis.
6. The method of claim 1 , wherein the immune disease is inflammatory bowel disease (IBD).
7. The method of claim 1 , wherein the immune disease is Crohn's disease.
8. The method of claim 1 , wherein the immune disease is atherosclerosis.
9. The method of claim 1 , wherein the immune disease is graft-vs-host disease (GVHD).
10. The method of claim 1 , wherein the immune disease is myasthenia gravis.
11. The method of claim 1 , wherein the antibody polypeptide further comprises an Fc domain.
12. The method of claim 11 , wherein the Fc domain comprises an IgG4 Fc domain.
13. The method of claim 11 , wherein the Fc domain comprises an IgG1 Fc domain.
14. The method of claim 11 , wherein the Fc domain comprises the amino acid sequence of amino acids 139 to 370 of SEQ ID NO: 1362.
15. The method of claim 14 , wherein the first variable domain consists of the amino acid sequence of SEQ ID NO: 274.
16. The method of claim 15 , wherein the Fc domain consists of the ammo acid sequence of ammo acids 139 to 370 of SEQ ID NO: 1362.
17. The method of claim 11 , wherein the first variable domain and the Fc domain are linked by an amino acid sequence selected from the group consisting of: AS, AST, TVAAPS (SEQ ID NO: 13), TVA, ASTSGPS (SEQ ID NO: 14) and (GGGGS) n (SEQ ID NO: 12) wherein n is 1, 2, 3, 4, or 5.
18. The method of claim 17 , wherein the first variable domain consists of the amino acid sequence of SEQ ID NO: 274.
19. The method of claim 18 , wherein the Fc domain consists of the amino acid sequence of amino acids 139 to 370 of SEQ ID NO: 1362.
20. The method of claim 1 , wherein the antibody polypeptide comprises the amino acid sequence of SEQ ID NO: 1355.